Trends in Consumption of Quinolones in Chinese Healthcare Institutions: Results of National Procurement Data Analysis (2015–2018)

Chen,Khezar Hayat,Sen Xu,Ali Hassan Gillani,Wenchen Liu,Jie chang,Caijun Yang,Wenjing Ji,Minghuan Jiang,Mingyue Zhao,Yu Fang
DOI: https://doi.org/10.21203/rs.3.rs-136461/v1
2020-01-01
Abstract:BackgroundThere is widespread use of quinolones to treat various infectious diseases due to their broad-spectrum nature and optimal pharmacokinetic characteristics. Nevertheless, the risk of bacterial resistance has also amplified as a consequence of their judicial use in hospitals and the community. The current study investigated the consumption and expenditure of quinolone antibiotics during 2015–2018 in various health settings in China.MethodsWe used the China Drug Supply Information Platform (CDSIP) to analyze the drug procurement data of national healthcare institutions, focusing on determining the trend and pattern of quinolone consumption. The standard Anatomical Therapeutic Chemical (ATC)/Defined daily dose (DDD) methodology was opted to quantify antibiotic usage.ResultsA slight decrease in J01M antibiotics consumption (25.7% to 23.5%) was observed over four years (2015–2018). The use of quinolones was significantly higher in rural primary health centers (53.9%) and tertiary hospitals (22.1%). In 2017, levofloxacin (61.4%) was the most commonly consumed quinolone, followed by norfloxacin (27.1%) and moxifloxacin (4.1%). The total spending on J01M antibiotics gradually increased from 21.4% in 2015 to 27.9% in 2018. ConclusionsFrom 2015 to 2018, the general use of J01M antibiotics decreased marginally, but the use of the paternal type of J01M and its expenditure is continuously growing. There is a need to enforce stringent antibiotic management programs to restrict the irrational use of antibiotics.
What problem does this paper attempt to address?